Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

| More on:
a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Telix Pharmaceuticals Ltd (ASX: TLX) shares have been on an absolute tear over the past year, surging an incredible 175%.

And according to the team at Bell Potter, this high-flying ASX 200 share may have even more room to run.

This morning, the broker has upgraded its recommendation on the radiopharmaceuticals company and lifted its price target meaningfully following the release of its full year results.

Why is the broker bullish on this ASX 200 share?

Despite a slight earnings miss with its FY 2024 results, Bell Potter sees enormous potential in Telix's expanding pipeline and strategic acquisitions.

It notes that the company recently released its results and revealed revenue of US$517 million (A$783 million), which was broadly in line with expectations. However, adjusted EBITDA of A$99.3 million came in 14% below consensus estimates.

Despite this, the market largely brushed off the earnings miss, focusing instead on Telix's strong growth outlook instead.

This is being underpinned by the acquisition of RLS Radiopharma, which is expected to contribute ~A$222 million in revenue, the launch of Pixclara, and the rapidly growing flagship product, Illuccix. The latter is forecast to grow its revenue by 24% to approximately A$1 billion in FY 2025.

In total, Telix has guided for FY 2025 revenue in the range of A$1.18 billion to A$1.23 billion, a notable increase from FY 2024.

Catalysts ahead

Telix remains aggressive in expanding its clinical pipeline, and Bell Potter sees multiple short-term catalysts that could drive further upside for this ASX 200 share. The company is pushing ahead with pivotal studies for TLX250 (a renal cancer treatment) and TLX101 (a therapy for glioma).

There's also significant anticipation around a potential FDA approval for Zircaix, a ccRCC imaging agent, with an announcement expected within weeks. Meanwhile, the company's ProstACT global study for prostate cancer is expected to deliver interim data in the first half of FY 2025.

Time to buy

Given these developments, Bell Potter has made wholesale changes to its earnings forecasts for Telix. This has led to the broker upgrading its shares to a buy rating and lifting its price target on them to $36.00 (from $21.60).

Based on its current share price of $30.12, this implies potential upside of almost 20% for investors over the next 12 months.

Commenting on the company, it said:

TLX remains laser-focused on accelerating its extensive clinical pipeline to market and will continue to spend aggressively through CY27 in order to achieve this goal.

Numerous changes to earnings following completion of RLS acquisition and devaluation of A$. PT is amended to $36.00 (from $21.60) and recommendation is upgraded to buy largely driven by short term catalysts for new product approvals.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »